Use of a peripherally implanted subcutaneous permanent central venous access device for chemotherapy--the Singapore General Hospital experience.
Venous access for chemotherapy patients at the Singapore General Hospital has conventionally been via an externalised (Hickman) catheter. A peripherally implanted permanent subcutaneous central venous access device (P.A.S.Port) was introduced in 1996. We review its use, complications and cost competitiveness with other chemotherapy delivery systems. A retrospective study of clinical records was conducted with follow up interviews of patients and nursing staff. Twelve patients had the P.A.S.Port inserted for administration of chemotherapy as an outpatient procedure. Immediate complications were pain (8%) and bruising (8%). One port-related infection (8%) one week following insertion was reported and one patient complained of interference with elbow movement as a late complication. Cost analysis was favourable for P.A.S.Port over an externalised Hickman catheter or chest-placed port at one year. Patient and nursing staff acceptance was high. P.A.S.Port insertion is a safe outpatient procedure and is an alternative for permanent venous access.